✦ LIBER ✦

Paclitaxel vs cyclophosphamide, + cisplatin, for ovarian cancer

Book ID: 120848265
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2007
Weight: 120 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200715810-00050

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cisplatin–paclitaxel treatment for advan

Cisplatin–paclitaxel treatment for advanced ovarian cancer resulted in longer survival than cisplatin–cyclophosphamide

✍ Franco Muggia 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 251 KB

531 - Cisplatin/paclitaxel vs carboplati

531 - Cisplatin/paclitaxel vs carboplatin/paclitaxel: Optimizing of treatment in advanced ovarian cancer

✍ V. Möbus; C. Jackisch; H.-J. Lück; W. Meier; T. Bauknecht; S. Costa; B. Richter; 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 248 KB

Cisplatin–Paclitaxel–Cyclophosphamide wi

Cisplatin–Paclitaxel–Cyclophosphamide with G-CSF in Primary Advanced Epithelial Ovarian Cancer

✍ James Fanning; Michael Colgrove; Garth Phibbs 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 42 KB

Cisplatin–paclitaxel improves progressio

Cisplatin–paclitaxel improves progression-free survival compared with cisplatin–cyclophosphamide in advanced epithelial ovarian cancer

✍ Robert F. Ozols 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 192 KB

Intraperitoneal Cisplatin and Paclitaxel

Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer

✍ Armstrong, Deborah K.; Bundy, Brian; Wenzel, Lari; Huang, Helen Q.; Baergen, Reb 📂 Article 📅 2006 🏛 Massachusetts Medical Society 🌐 English ⚖ 751 KB

Paclitaxel plus cisplatin favoured in ov

Paclitaxel plus cisplatin favoured in ovarian cancer

📂 Article 📅 1999 🏛 Adis International Limited (now part of Wolters Kl ⚖ 129 KB